Abstract
We measured serum ubiquinone and dolichol concentrations in 13 men while they abused anabolic androgenic steroids (AAS) and during the following withdrawal period. Serum total, high-density lipoprotein (HDL), and low- density lipoprotein (LDL) cholesterol and triglycerides were also determined. AAS administration increased serum ubiquinone by 68% (P < .001) and decreased serum dolichol by 30% (P < .002). Both nonsterol isoprenoid levels in plasma correlated with the AAS dose, ubiquinone positively (P < .001) and dolichol negatively (P < .002). When the subjects were taking steroids, the ubiquinone to LDL ratio was 42% higher than during the withdrawal period. In conclusion, our study suggests that AAS have an influence on the by-products of the mevalonate pathway.
Cite
CITATION STYLE
Karila, T., Laaksonen, R., Jokelainen, K., Himberg, J. J., & Seppälä, T. (1996). The effects of anabolic androgenic steroids on serum ubiquinone and dolichol levels among steroid abusers. Metabolism: Clinical and Experimental, 45(7), 844–847. https://doi.org/10.1016/S0026-0495(96)90157-2
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.